Antibody-drug conjugates can deliver chemotherapy directly to tumors but more than 95 percent of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Mythic Therapeutics FateControl technology improves the uptake of ADCs in cancerous cells while avoiding the release of their toxic payloads in healthy ones. This promises to increase efficacy of these therapies in a wide range of cancers without causing unacceptable side-effects. We spoke to Brian Fiske, co-founder, chief scientific officer of Mythic, about the challenges that have held back the benefits of ADCs, how the company’s FateControl technology addresses those, and how it is thinking of building a pipeline of ADCs across indications.
Targeting a Regulator of Inflammation to Treat Alzheimer’s Disease
Enabling Regenerative Therapies without Immunosuppression
Making Vaccine and Biotherapeutic Production Fast and Affordable
Forcing Cancers to Reveal Themselves
Making Clinical Trials Diverse and Accessible
Mining Bugs for Drugs
A Company That Bets Its Therapies Will Click with Patients
A Company Where It takes Guts and Brains to Develop Drugs
Changing Outcomes with Data
Treating Psychiatric Conditions with Tripless Psychedelics
How AI Is Finding Its Way into Unexpected Places in Biopharma Companies
Searching the Dark Matter of the Proteome to Develop New Therapies
The Year in Biotech and What’s Ahead in 2023
Targeting a Novel Checkpoint to Treat Cancer and Autoimmune Conditions
The Growing Need for Biosecurity Vigilance
Enlisting Next-Generation Cytokine Immunotherapies in the Fight Against Cancer
Engineering Safer and More Effective Cell Therapies
Changing Drug Discovery for Neuropsychiatric Disorders with Phenotypic Screens
Using Virtual Reality-Guided Mindfulness to Treat Chronic Pain in Cancer Patients
Activating the Adaptive and Innate Immune Systems to Fight Cancer
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Ground Truths